Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients
Table 2
Genotype frequency distribution of P2RY12 polymorphisms in KD patients resistant or sensitive to IVIG therapy.
Genotype
IVIG R (n = 148)
IVIG S (n = 611)
valuea
OR (95% CI)
value
Adjusted OR (95% CI)
valueb
P2RY12/rs9859538 G > A HWE = 0.4397
GG
106 (71.62%)
444 (72.67%)
0.8268
1.00
1.00
GA
37 (25.00%)
152 (24.88%)
1.02 (0.67–1.55)
0.9273
1.02 (0.67–1.55)
0.9327
AA
5 (3.38%)
15 (2.45%)
1.40 (0.50–3.93)
0.5267
1.41 (0.50–3.98)
0.5130
Dominant
42 (28.38%)
167 (27.33%)
0.7982
1.05 (0.81–1.57)
0.7983
1.05 (0.71–1.57)
0.7992
Recessive
143 (96.62%)
596 (97.55%)
0.5419
1.39 (0.50–3.89)
0.5306
1.41 (0.50–3.94)
0.5164
P2RY12/rs1491974 A > G HWE = 0.3464
AA
46 (31.08%)
180 (29.46%)
0.9124
1.00
1.00
AG
75 (50.68%)
313 (51.23%)
0.94 (0.62–141)
0.7584
0.95 (0.63–1.43)
0.8003
GG
27 (18.24%)
118 (19.31%)
0.90 (0.53–1.52)
0.6821
0.90 (0.53–1.52)
0.6866
Dominant
102 (68.92%)
431 (70.54%)
0.6997
0.93 (0.63–1.37)
0.6988
0.93 (0.63–1.38)
0.7313
Recessive
121 (81.76%)
493 （80.69%)
0.7655
0.93 (0.59–1.48)
0.7666
0.93 (0.58–1.47)
0.7486
P2RY12/rs7637803 C > T HWE = 0.8563
CC
109 (73.65%)
433 (70.87%)
0.7686
1.00
1.00
CT
36 (24.32%)
162 (26.51%)
0.88 (0.58–1.34)
0.5586
0.88 (0.58–1.34)
0.5593
TT
3 (2.03%)
16 (2.62%)
0.75 (0.21–2.60)
0.6445
0.75 (0.21–2.62)
0.6515
Dominant
39 (26.35%)
178 (29.13%)
0.4990
0.87 (0.58–1.31)
0.5019
0.87 (0.58–1.31)
0.5040
Recessive
145 (97.97%)
595 (97.38%)
0.6715
0.77 (0.22–2.68)
0.6803
0.77 (0.22–2.69)
0.6871
P2RY12/rs6809699 A > C HWE = 0.4890
AA
132 (89.19%)
487 (79.71%)
0.0194
1.00
1.00
AC
15 (10.14%)
116 (18.99%)
0.48 (0.27–0.85)
0.011
0.48 (0.27–0.84)
0.0110
CC
1 (0.68%)
8 (1.31%)
0.46 (0.6–3.72)
0.468
0.44 (0.06–3.58)
0.4449
Dominant
16 (10.81%)
124 (20.29%)
0.0050
0.48 (0.27–0.83)
0.009
0.47 (0.27–0.83)
0.0084
Recessive
147 (99.32%)
603 (98.69%)
0.4949
0.51 (0.06–4.13)
0.5304
0.49 (0.06–3.99)
0.5069
P2RY12/rs2046934 G > A HWE = 0.0690
GG
114 (77.03%)
443 (72.50%)
0.4278
1.00
1.00
GA
29 (19.59%)
150 (24.55%)
0.75 (0.48–1.18)
0.2107
0.75 (0.48–1.67)
0.2002
AA
5 (3.38%)
18 (2.95%)
1.08 (0.39–2.97)
0.8823
1.07 (0.39–2.95)
0.8946
Dominant
34 (22.97%)
168 (27.50%)
0.2583
0.79 (0.52–1.20)
0.2648
0.78 (0.51–1.19)
0.2513
Recessive
143 (96.62%)
593 (97.05%)
0.7859
1.15 (0.42–3.12)
0.7832
1.15 (0.42–3.14)
0.7927
Combined effect of protective genotypes
0–3
140 (94.59%)
507 (82.98%)
<0.0001
1.00
1.00
4–5
8 (5.41%)
104 (17.02%)
0.27 (0.13–0.57)
0.0006
0.27 (0.13–0.57)
0.0006
aTwo-sided χ2 test for distributions between Kawasaki disease patients with IVIG resistance and IVIG sensitivity. bAdjusted for age and gender status in logistic regress models.
